Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Income from Continuing Operations (2016 - 2023)

RedHill Biopharma has reported Income from Continuing Operations over the past 12 years, most recently at 58921000.0 for Q2 2023.

  • Quarterly Income from Continuing Operations rose 791.8% to 58921000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 40004000.0 through Jun 2023, up 64.44% year-over-year, with the annual reading at 8080000.0 for FY2025, 2344.44% down from the prior year.
  • Income from Continuing Operations was 58921000.0 for Q2 2023 at RedHill Biopharma, up from 7919000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 58921000.0 in Q2 2023 and troughed at 145245000.0 in Q4 2021.
  • The 5-year median for Income from Continuing Operations is 11059500.0 (2019), against an average of 1308111.11.
  • Year-over-year, Income from Continuing Operations plummeted 1062.84% in 2021 and then skyrocketed 791.8% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 11837000.0 in 2019, then increased by 27.44% to 15085000.0 in 2020, then plummeted by 1062.84% to 145245000.0 in 2021, then soared by 52.14% to 69521000.0 in 2022, then surged by 184.75% to 58921000.0 in 2023.
  • Per Business Quant, the three most recent readings for RDHL's Income from Continuing Operations are 58921000.0 (Q2 2023), 7919000.0 (Q1 2023), and 69521000.0 (Q4 2022).